Zobrazeno 1 - 10
of 37
pro vyhledávání: '"Abstracts from the 3rd Sno-Scidot Joint Conference on Therapeutic Delivery to the CNS"'
Autor:
George Ansstas, Jian Campian, David Tran, Joshua S. Shimony, Eric C. Leuthardt, Albert H. Kim
Publikováno v:
Neuro Oncol
BACKGROUND Poor CNS drug delivery is a major limiting factor in GBM therapy. Since most recurrences occur peritumorally where infiltrating glioma cells reside, peritumoral BBB disruption may help improve drug delivery and efficacy. LITT, a minimally
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c271146bd546e59240c75ffbfcb5b17e
https://europepmc.org/articles/PMC6847033/
https://europepmc.org/articles/PMC6847033/
Autor:
Jann N. Sarkaria, Minjee Kim, Afroz S. Mohammad, Steven S. Rosenfeld, Gautham Gampa, William F. Elmquist, Karen E. Parrish, Rajappa S. Kenchappa
Publikováno v:
Neuro Oncol
Glioblastoma, the most common and lethal of brain tumors, is both highly invasive and proliferative. This allows tumor cells to infiltrate into regions of the brain with an intact blood brain barrier and be protected from effective therapeutics. Thus
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::744301142e04d3a9fad3b750ca416268
https://europepmc.org/articles/PMC6845720/
https://europepmc.org/articles/PMC6845720/
Publikováno v:
Neuro Oncol
Glioblastoma multiforme (GBM), is the most aggressive form of glioma, a brain tumor that arises from glial cells. GBM is considered a complex malignancy with multiple gene mutations, aberrations, and overexpression together with high infiltration rat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::029d0d0768f10ba7ba762835f3882e29
https://europepmc.org/articles/PMC6846496/
https://europepmc.org/articles/PMC6846496/
Autor:
Maria Ribadeneira, Lili Yao, Paul Ehrlich, Angela Toms, Sylvie Guichard, Sanjeev Forsyth, Blythe Thomson
Publikováno v:
Neuro Oncol
BACKGROUND Iocitrate dehydrogenase mutations (mIDH1) are present in >70% of patients with Grade II/III gliomas resulting in production and accumulation of (R)-2-hydroxyglutarate (2-HG) causing DNA hypermethylation and promoting tumorigenesis. This ab
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a628c47b58cca650a0d64393a8f0662
https://europepmc.org/articles/PMC6845728/
https://europepmc.org/articles/PMC6845728/
Autor:
Hiroto Kiguchi, Mandana Manzari, Jake Vaynshteyn, Jeffrey Gerwin, Daniel Tylawsky, Na Li, Janki Shah, Yosi Shamay, Matthew Greenblatt, Daniel Heller, G Praveen Raju
Publikováno v:
Neuro Oncol
OBJECTIVE The Sonic Hedgehog (SHH) medulloblastoma subgroup accounts for ~25% of all cases and has an intermediate prognosis. Current conventional therapies result in devastating morbidities including intellectual disability and secondary malignancie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c875c5984b4aa4bca157751c857ed738
https://europepmc.org/articles/PMC6846632/
https://europepmc.org/articles/PMC6846632/
Publikováno v:
Neuro Oncol
BACKGROUND The Hælo pediatric system, an investigational medical device intended to treat diffuse midline glioma (DMG), emits a magnetic field intended to disrupt the growth of DMG tumors. The Hælo headcoil is positioned on the back of the patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e79f3d85c84c607101a960404ef571e
https://europepmc.org/articles/PMC6846560/
https://europepmc.org/articles/PMC6846560/
Publikováno v:
Neuro Oncol
BACKGROUND The incidence of abnormal CSF flow dynamics in the pediatric population with CNS tumors prior to intraventricular therapy has not been described. METHODS We performed a single-institution, retrospective review of patients with primary or m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a60acde4cb881bf816b2833caff5fb20
https://europepmc.org/articles/PMC6846473/
https://europepmc.org/articles/PMC6846473/
Autor:
Qixue Wang, Junhu Zhou, Chunsheng Kang, Yanli Tan, Luyue Chen, Yunfei Wang, Yingbin Xie, Chuan Fang
Publikováno v:
Neuro Oncol
Mesenchymal subtype of glioblastoma (mesGBM) is a refractory disease condition characterized by therapeutic failure and tumor recurrence, and for the past decade, no treatment option has improved the dismal prognosis of this disease. In Cancer Genome
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20850c34b732dd4bd451b0e29465386e
https://europepmc.org/articles/PMC6846567/
https://europepmc.org/articles/PMC6846567/
Autor:
David Johnson, Steven S Gill, Paul Skinner, Owen Lewis, Clare L Killick-Cole, Max Woolley, Alison Bienemann
Publikováno v:
Neuro Oncol
Previous research and clinical trials have highlighted the utility of convection-enhanced delivery (CED) to directly administer therapeutics to the brain. This method bypasses the blood-brain barrier, which is a major obstacle in systemic drug delive
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b9263642428afa83120204b00698026
https://europepmc.org/articles/PMC6846196/
https://europepmc.org/articles/PMC6846196/
Autor:
Taylor Dismuke, William C. Zamboni, Duhyeong Hwang, Elias P. Rosen, Alexander V. Kabanov, Marina Sokolsky-Papkov, Timothy R. Gershon, John R. Kagel, Chaemin Lim
Publikováno v:
Neuro Oncol
Systemic therapies for brain tumors are complicated by dose-limiting extraneural toxicity, serum protein binding and restricted blood-brain barrier (BBB) permeability. For patients with SHH-subgroup medulloblastoma, SHH-pathway inhibition may be more
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e8192150c0fb929987fc8cc08273ba81
https://europepmc.org/articles/PMC6845657/
https://europepmc.org/articles/PMC6845657/